S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Is This The End of Capitalism? (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
The Next Big Crisis Is Here (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Is This The End of Capitalism? (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
The Next Big Crisis Is Here (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Is This The End of Capitalism? (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
The Next Big Crisis Is Here (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Is This The End of Capitalism? (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
The Next Big Crisis Is Here (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
NASDAQ:SCPH

scPharmaceuticals - SCPH Stock Forecast, Price & News

$5.59
-0.10 (-1.76%)
(As of 01/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$5.50
$5.89
50-Day Range
$5.59
$7.53
52-Week Range
$3.68
$7.96
Volume
250,873 shs
Average Volume
220,688 shs
Market Capitalization
$153.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

scPharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
222.0% Upside
$18.00 Price Target
Short Interest
Bearish
8.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.90
Upright™ Environmental Score
News Sentiment
0.54mentions of scPharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
$4 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.42) to ($1.57) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

605th out of 1,049 stocks

Pharmaceutical Preparations Industry

303rd out of 514 stocks


SCPH stock logo

About scPharmaceuticals (NASDAQ:SCPH) Stock

scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include FUROSCIX, a furosemide injection which is used as parenteral diuretic in treating heart failure and scCeftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.

Receive SCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SCPH Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
What Makes scPharmaceuticals, Inc. (SCPH) a New Buy Stock
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
See More Headlines
Receive SCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SCPH Company Calendar

Last Earnings
11/09/2022
Today
1/31/2023
Next Earnings (Estimated)
3/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SCPH
Fax
N/A
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.00
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+222.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-28,030,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.06 per share

Miscellaneous

Free Float
26,145,000
Market Cap
$153.36 million
Optionable
Not Optionable
Beta
0.25

Key Executives

  • John H. Tucker
    President, Chief Executive Officer & Director
  • Rachael Nokes
    Treasurer, Chief Financial & Accounting Officer
  • John Mohr
    Senior VP-Clinical Development & Medical Affairs
  • Mike Hassman
    Senior Vice President-Technical Operations
  • Katherine Taudvin
    Director-IR & Corporate Development













SCPH Stock - Frequently Asked Questions

Should I buy or sell scPharmaceuticals stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SCPH shares.
View SCPH analyst ratings
or view top-rated stocks.

What is scPharmaceuticals' stock price forecast for 2023?

6 Wall Street research analysts have issued 12 month price objectives for scPharmaceuticals' shares. Their SCPH share price forecasts range from $13.00 to $25.00. On average, they predict the company's share price to reach $18.00 in the next year. This suggests a possible upside of 222.0% from the stock's current price.
View analysts price targets for SCPH
or view top-rated stocks among Wall Street analysts.

How have SCPH shares performed in 2023?

scPharmaceuticals' stock was trading at $7.17 at the start of the year. Since then, SCPH shares have decreased by 22.0% and is now trading at $5.59.
View the best growth stocks for 2023 here
.

Are investors shorting scPharmaceuticals?

scPharmaceuticals saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 1,700,000 shares, an increase of 36.0% from the December 31st total of 1,250,000 shares. Based on an average trading volume of 241,900 shares, the days-to-cover ratio is presently 7.0 days. Currently, 8.4% of the shares of the stock are short sold.
View scPharmaceuticals' Short Interest
.

When is scPharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our SCPH earnings forecast
.

How were scPharmaceuticals' earnings last quarter?

scPharmaceuticals Inc. (NASDAQ:SCPH) issued its quarterly earnings data on Wednesday, November, 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.04.

What other stocks do shareholders of scPharmaceuticals own?
When did scPharmaceuticals IPO?

(SCPH) raised $96 million in an IPO on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is scPharmaceuticals' stock symbol?

scPharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."

Who are scPharmaceuticals' major shareholders?

scPharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Thomasville National Bank (0.12%), FNY Investment Advisers LLC (0.08%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include 5Am Partners Iv, Llc, Andrew J Schwab, Jack A Khattar, John H Tucker, Orbimed Advisors Llc and Ra Capital Management, LP.
View institutional ownership trends
.

How do I buy shares of scPharmaceuticals?

Shares of SCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is scPharmaceuticals' stock price today?

One share of SCPH stock can currently be purchased for approximately $5.59.

How much money does scPharmaceuticals make?

scPharmaceuticals (NASDAQ:SCPH) has a market capitalization of $153.36 million. The company earns $-28,030,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis.

How can I contact scPharmaceuticals?

scPharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The official website for the company is www.scpharma.com. The company can be reached via phone at (617) 517-0730 or via email at tignelzi@scpharma.com.

This page (NASDAQ:SCPH) was last updated on 1/31/2023 by MarketBeat.com Staff